Researchers at Osaka Metropolitan University have developed a method to generate red blood cell-like cells from canine induced pluripotent stem cells (iPSCs). By using CRISPR-Cas9 to target glycophorin A (GYPA), the team achieved 96% marker expression, though only 3% of the cells reached full maturity via enucleation, according to findings published in Stem Cells Translational Medicine.
Canine iPSC Differentiation and CRISPR Tracking
The research team, led by Professor Shingo Hatoya at the Osaka Metropolitan University Graduate School of Veterinary Science, utilized canine iPSCs developed in collaboration with TOKIWA-Bio Inc. The process involved culturing the cells as clusters to mimic the natural embryonic development of blood. As the cells progressed, they began producing hemoglobin, the essential protein responsible for oxygen transport in mammals.
To monitor this transition, the team employed CRISPR-Cas9 genome editing to target GYPA. Cells expressing this specific red blood cell marker were engineered to fluoresce green. This real-time visualization allowed the researchers to confirm that the vast majority of their cultured cells—over 96%—successfully reached the red blood cell-like stage, providing a robust platform for further study.
Did you know?
While human blood banks are common, veterinary medicine relies almost exclusively on donations from healthy donor dogs. Because dogs possess distinct blood types, finding compatible matches during emergencies remains a significant clinical hurdle.
The Path Toward Transfusion-Ready Blood
Despite the high rate of GYPA expression, the cells are not yet ready for clinical transfusion. Professor Hatoya noted that only 3% of the lab-grown cells successfully underwent enucleation—the process where a cell sheds its nucleus to become a functional, mature red blood cell. This maturation step is critical for oxygen delivery and cell longevity within a patient’s circulatory system.
Future research will prioritize increasing this enucleation rate and investigating why different cell lines behave differently during the differentiation process. The findings are expected to serve as a dual-purpose resource: helping to bridge the gap in veterinary blood supplies while acting as a translational model for human regenerative medicine.
Translational Benefits for Human and Veterinary Medicine
The similarities between human and canine physiology make dogs an ideal model for testing stem cell therapies. By perfecting the creation of red blood cells in the lab, scientists can better understand the underlying mechanisms of blood disorders and the potential for synthetic blood alternatives. This study establishes a foundational protocol that may eventually assist in the development of standardized, iPSC-derived blood products for both human and veterinary applications.
Frequently Asked Questions
- Why is it difficult to get canine blood for transfusions?
Veterinary blood banks are rare, and dogs have complex blood types that make finding compatible donors a frequent logistical challenge in emergency care. - What is the role of CRISPR-Cas9 in this study?
Researchers used CRISPR-Cas9 to make the cells glow green when they expressed GYPA, allowing for real-time tracking of red blood cell development. - Are these cells ready for use in dogs?
No. Currently, the cells are not fully mature. Only 3% of the generated cells successfully completed the enucleation process required for functional red blood cells.
If you are interested in the intersection of veterinary science and regenerative medicine, keep an eye on developments in “translational models,” which use canine health data to inform human clinical trials.
For more updates on advancements in stem cell research and veterinary medicine, subscribe to our newsletter or browse our science archives. Have questions about this research? Leave a comment below.
Related reading